There is interest in the potential of psychedelics as treatments for Obsessive-Compulsive and Related Disorders (OCRDs), though research in this field is still at an early stage. In this review, we examine the methodological issues present in existing research investigating the use of psychedelics in OCRDs, as a basis for improved trial design. We searched PubMed and PsycInfo for published...
Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency. While its clinical efficacy and safety are proven, the mechanisms underlying its antidepressant effect remain unclear. The use of metabolomics may allow...